A leukemia expert discusses ongoing challenges in chronic lymphocytic leukemia treatment, and how to discuss risk stratification with a patient.
Case: A 70-Year-Old Woman with Newly Diagnosed Chronic Lymphocytic Leukemia
Initial Presentation:
Treatment:
In CLL/SLL, Zanubrutinib Linked to Lower Switch Rates vs Other BTK Inhibitors
September 12th 2024Findings from a real-world study showed that zanubrutinib was associated with lower rates of treatment switching and patients receiving subsequent therapy compared with acalabrutinib and ibrutinib in patients with CLL or SLL.
Read More